Our Lady of the Lake Cancer Institute is celebrating after successfully completing a bone marrow transplant so rare it has ...

Dr. Reddy's (RDY) partners with Shanghai Henlius Biotech to develop and market biosimilar versions of J&J's (JNJ) multiple ...

In this video, Sham Mailankody, MBBS discusses the current state of the pipeline for developing multiple myeloma treatments.

One of the biggest risk is probably aging, myeloma is more common as people grow older. So the median age at which patients get diagnosed with myeloma is about 68/69 years. So it's still predominantly ...

The 100 Black Men of South Florida, Inc. (The 100) and Pfizer Pharmaceuticals partner to host health awareness programming ...

The phase 2 REST trial by Frida Bugge Askeland and colleagues, reported in The Lancet Haematology, provides insight into ...

The panelist discusses how for managing patients with R/R multiple myeloma, community clinicians should focus on personalized ...

Sanofi has received China’s National Medical Products Administration (NMPA) approval for the use of Sarclisa (isatuximab), ...

Ashraf Z. Badros, MB, ChB, discusses the next steps following the phase 3 AURIGA trial of daratumumab and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

Study reveals VLCFA metabolism as a key target in multiple myeloma, enhancing drug efficacy and overcoming resistance.

The following is a summary of “Time-dependent recovery of renal impairment in patients with newly diagnosed multiple myeloma, ...